A meta-analysis of observational studies of patients with retroperitoneal sarcoma (RPS) has shown that these patients may have significantly better outcomes if they are administered neoadjuvant radiation therapy (NART) (J Surg Oncol 2016 Mar 16. [Epub ahead of print], PMID: 26990903). The review of 15 published articles including 464 patients who received NART showed a five-year overall survival of up to 90%, which is significantly better than the reported overall survival of up to 75%
APRIL 7, 2016